Thomas Schwartz

Summary

Publications

  1. ncbi request reprint An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Ann Clin Psychiatry 19:25-30. 2007
  2. ncbi request reprint Gamma hydroxy butyric acid and sodium oxybate used to treat posttraumatic stress disorder
    Thomas L Schwartz
    Department of Psychiatry, State University of New York, Upstate Medical University, Syracuse, New York, USA
    CNS Spectr 12:884-6. 2007
  3. ncbi request reprint Psychiatric medication-induced obesity: treatment options
    T L Schwartz
    SUNY Upstate Medical University, Department of Psychiatry, Syracuse, NY 13210, USA
    Obes Rev 5:233-8. 2004
  4. ncbi request reprint Psychiatric medication-induced obesity: a review
    T L Schwartz
    SUNY Upstate Medical University, Department of Psychiatry, Syracuse, NY 13210, USA
    Obes Rev 5:115-21. 2004
  5. ncbi request reprint Pharmacokinetics and drug interactions of the sedative hypnotics
    Thomas L Schwartz
    Upstate Medical University, State University of New York, Syracuse, New York, USA
    Psychopharmacol Bull 37:5-9. 2003
  6. ncbi request reprint History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders
    T L Schwartz
    Psychiatry Department, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Curr Pharm Des 11:255-63. 2005
  7. ncbi request reprint An open-label study of tiagabine as augmentation therapy for anxiety
    Thomas L Schwartz
    SUNY Upstate Medical University, Department of Psychiatry, 750 East Adams Street, Syracuse, NY 13210, USA
    Ann Clin Psychiatry 17:167-72. 2005
  8. ncbi request reprint Tiagabine in anxiety disorders
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA
    Expert Opin Pharmacother 7:1977-87. 2006
  9. ncbi request reprint Modafinil treatment for fatigue associated with fibromyalgia
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical Univeristy, Syracuse, New York 13210, USA
    J Clin Rheumatol 13:52. 2007
  10. ncbi request reprint Safety and tolerability of extended-release venlafaxine in severe medical and surgical illness
    Thomas Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Psychosomatics 45:217-9. 2004

Collaborators

Detail Information

Publications27

  1. ncbi request reprint An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Ann Clin Psychiatry 19:25-30. 2007
    ....
  2. ncbi request reprint Gamma hydroxy butyric acid and sodium oxybate used to treat posttraumatic stress disorder
    Thomas L Schwartz
    Department of Psychiatry, State University of New York, Upstate Medical University, Syracuse, New York, USA
    CNS Spectr 12:884-6. 2007
  3. ncbi request reprint Psychiatric medication-induced obesity: treatment options
    T L Schwartz
    SUNY Upstate Medical University, Department of Psychiatry, Syracuse, NY 13210, USA
    Obes Rev 5:233-8. 2004
    ..There is a clear need for larger studies on existing options, and future psychotropics without these side-effects are currently in the pipeline...
  4. ncbi request reprint Psychiatric medication-induced obesity: a review
    T L Schwartz
    SUNY Upstate Medical University, Department of Psychiatry, Syracuse, NY 13210, USA
    Obes Rev 5:115-21. 2004
    ....
  5. ncbi request reprint Pharmacokinetics and drug interactions of the sedative hypnotics
    Thomas L Schwartz
    Upstate Medical University, State University of New York, Syracuse, New York, USA
    Psychopharmacol Bull 37:5-9. 2003
    ..The results showed that orlistat, administered in 3 daily doses with meals, was safe, well-tolerated, and effective, resulting in an average weight loss of 35% during an acute treatment period of about 3 months...
  6. ncbi request reprint History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders
    T L Schwartz
    Psychiatry Department, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Curr Pharm Des 11:255-63. 2005
    ..The following paper details the pharmacodynamic history of treating anxiety and also updates the reader as to the newer GABA-based approaches mentioned above...
  7. ncbi request reprint An open-label study of tiagabine as augmentation therapy for anxiety
    Thomas L Schwartz
    SUNY Upstate Medical University, Department of Psychiatry, 750 East Adams Street, Syracuse, NY 13210, USA
    Ann Clin Psychiatry 17:167-72. 2005
    ..Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the CNS, and agents that modulate GABA neurotransmission have shown promise in the treatment of anxiety disorders and are often used as augmentation agents...
  8. ncbi request reprint Tiagabine in anxiety disorders
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA
    Expert Opin Pharmacother 7:1977-87. 2006
    ..Tiagabine may be a useful addition to currently available drugs for anxiety; however, the data from small open-label investigations remain to be confirmed in larger controlled studies...
  9. ncbi request reprint Modafinil treatment for fatigue associated with fibromyalgia
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical Univeristy, Syracuse, New York 13210, USA
    J Clin Rheumatol 13:52. 2007
  10. ncbi request reprint Safety and tolerability of extended-release venlafaxine in severe medical and surgical illness
    Thomas Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Psychosomatics 45:217-9. 2004
    ..This study attempted to determine if extended-release venlafaxine is safe for use in severely medically and surgically ill depressed patients...
  11. ncbi request reprint A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression
    Mark S George
    Department of Psychiatry, Medical University of South Carolina, 67 President Street 502 N, Charleston, SC 29425, USA
    Biol Psychiatry 58:364-73. 2005
    ..To better understand these effects on long-term outcome, we compared 12-month VNS+TAU outcomes with those of a comparable TRD group...
  12. ncbi request reprint "A comparison of the effectiveness of two hypnotic agents for the treatment of insomnia"
    Thomas Schwartz
    SUNY Upstate Medical University, Department of Psychiatry, 750 East Adams Street, Syracuse, NY 13210, USA
    Int J Psychiatr Nurs Res 10:1146-50. 2004
    ..To compare the effectiveness and tolerability of two hypnotic agents, trazadone (Desyrel) and zaleplon (Sonata) on psychiatric inpatients with insomnia...
  13. ncbi request reprint Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits
    T L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York 13210, USA
    Ann Clin Psychiatry 13:159-62. 2001
    ..Furthermore, as sales visits increase in frequency, more of their medications may be started in newly admitted psychiatric outpatients...
  14. ncbi request reprint Psychiatric medication induced obesity: an aetiologic review
    S Virk
    Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    Obes Rev 5:167-70. 2004
    ..It is found that most psychotropic medications induce some weight gain, and clinicians are encouraged to utilize active interventions to alleviate the weight gain in order to prevent more serious obesity related comorbidities...
  15. ncbi request reprint Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Biol Psychiatry 58:355-63. 2005
    ..The need for effective, long-term treatment for recurrent or chronic, treatment-resistant depression is well established...
  16. ncbi request reprint An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy
    Thomas L Schwartz
    Department of Psychiatry, State University of New York Upstate Medical University, Syracuse, NY 13210, USA
    J Clin Psychiatry 65:1223-7. 2004
    ..This study assessed the use of modafinil as an adjunctive treatment in patients with MDD who reported sedation related to serotonergic antidepressant therapy...
  17. ncbi request reprint The role of atypical antipsychotics in the treatment of delirium
    Thomas L Schwartz
    Department of Psychiatry, S U N Y Upstate Medical University, Syracuse 13210, USA
    Psychosomatics 43:171-4. 2002
    ..g., schizophrenia or bipolar disorder), but few studies have evaluated them in the treatment of delirium. This paper reviews the pertinent literature and summarizes tentative guidelines for novel antipsychotic use in delirium...
  18. ncbi request reprint Modafinil in the treatment of depression with severe comorbid medical illness
    Thomas L Schwartz
    Psychosomatics 43:336-7. 2002
  19. ncbi request reprint The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    Psychopharmacol Bull 36:53-7. 2002
    ..Like other anticonvulsant agents, tiagabine has been explored for use as a mood stabilizer and in panic disorder. This article presents a case series of five patients who were prescribed tiagabine for treatment-resistant anxiety...
  20. ncbi request reprint Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome?
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
    Psychosomatics 43:451-5. 2002
    ..Both groups had similar improvement in abdominal pain, constipation, diarrhea, incomplete emptying, and bloating/ abdominal distension. Paroxetine was very well tolerated...
  21. ncbi request reprint Use of atypical antipsychotics in a Veterans Affairs hospital
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, New York, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:1207-10. 2002
    ....
  22. ncbi request reprint Effectiveness of orlistat versus diet and exercise for weight gain associated with antidepressant use: a pilot study
    Thomas L Schwartz
    J Clin Psychopharmacol 24:555-6. 2004
  23. doi request reprint Psychiatric resident and attending diagnostic and prescribing practices
    Adam C Tripp
    SUNY Upstate Medical University, Syracuse, NY 13210, USA
    Acad Psychiatry 32:214-7. 2008
    ..This study investigates whether two patient population groups, under resident or attending treatment, are equivalent or different in the distribution of patient characteristics, diagnoses, or pharmacotherapy...
  24. ncbi request reprint Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues
    Prakash S Masand
    Duke University Medical Center, Department of Psychiatry, Durham, North Carolina, USA
    Am J Ther 9:484-7. 2002
    ..066, df = 2, Pearson chi(2) test). For patients who are receiving any antipsychotic therapy, discussions about the risks/benefits of treatments are integral for optimal treatment and medicolegal purposes...
  25. ncbi request reprint Antidepressant treatment in the primary care office: outcomes for adjustment disorder versus major depression
    Usman Hameed
    Department of Psychiatry, Upstate Medical University, 750 E Adams Street, Syracuse, NY 13210, USA
    Ann Clin Psychiatry 17:77-81. 2005
    ..Our objective was to determine if there is a difference in antidepressant effectiveness between disorders in the newer antidepressants (SSRIs) in a primary care setting when a formal systematic depression treatment protocol is used...
  26. ncbi request reprint Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression
    Nikhil D Nihalani
    State University of New York, Upstate Medical University, Department of Psychiatry, Syracuse, New York, NY 13210 2375, USA
    Curr Opin Investig Drugs 8:563-9. 2007
    ..In addition, in March 2005 a phase II study of mifepristone as a cognitive enhancer in AD was underway, and in May 2006 a proof-of-concept study in alleviating the weight gain associated with olanzapine had begun...
  27. ncbi request reprint Ziprasidone treatment of delirium
    Laura Leso
    SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
    Psychosomatics 43:61-2. 2002